BioWorld

March 22, 2004

Critical Therapeutics Files For Estimated $103.5M IPO

Makeup Of Bush's Bioethics Committee Comes Under Fire

Chiron's Tezacitabine Scrapped After Phase II Trial Misses Goal

Other News To Note

$100M In Private Funds Expected To Expand Neurogen's Portfolio

Neurogen Corp.'s stock rose on Friday, following news that the company entered an agreement to privately sell $100 million worth of common shares. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...